01 January 2002
Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma - a double-blind randomized placebo-controlled multicentre clinical trial
Marc F Goldstein, Paul ChervinskyMed Sci Monit 2002; 8(4): CR297-304 :: ID: 420864
Abstract
BACKGROUND: Experimental studies have shown that doxofylline is endowedwith a remarkable bronchodilator activity with less extra-respiratory effects than theophylline. Thistrial was designed to compare the efficacy and safety of doxofylline, theophylline, and placebo in patientswith chronic reversible bronchial asthma. MATERIAL/METHODS: Three hundred forty-six patients were randomlyassigned to a 12-week oral treatment with either doxofylline 400 mg t.i.d. (high dose), doxofylline 200mg t.i.d. (low dose), theophylline 250 mg t.i.d. (active control) or placebo. Pulmonary function tests(PFTs) were performed biweekly. Patients kept records of peak flow meter (PFM) measurements, asthma attackrate and beta-2-agonist use (albuterol). RESULTS: Changes in FEV1 2 hours after the administration oftreatments versus baseline exhibited statistically significant differences between doxofylline 400 mgt.i.d. and placebo and between theophylline and placebo. Similar differences were monitored on the othervariables (FVC, PFER, FEF(25-75%). Asthma attack rate and use of albuterol decreased remarkably withdoxofylline 400 mg t.i.d. and theophylline. There were few statistically significant differences betweendoxofylline 200 mg t.i.d. and placebo. Significantly more patients had to interrupt treatment becauseof adverse events under theophylline than under doxofylline 400 mg t.i.d. (p=0.001). With doxofylline400 mg t.i.d., the number of patients treated to spare one drop-out due to theophylline was 5. CONCLUSIONS:This study provides evidence that doxofylline 400 mg t.i.d. is an effective treatment for relieving airwayobstruction and displays a better safety profile with respect to theophylline 250 mg t.i.d. with a favorablerisk-to-benefit ratio.
Keywords: Adrenergic beta-Agonists, Albuterol, Anti-Asthmatic Agents, Asthma, Comparative Study, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Forced Expiratory Volume, Gastrointestinal Diseases, Headache, Placebos, Respiratory Function Tests, Safety, Single-Blind Method, Tachycardia, Theophylline
Editorial
01 September 2024 : Editorial
Editorial: Reasons for Increasing Global Concerns for the Spread of MpoxDOI: 10.12659/MSM.946343
Med Sci Monit 2024; 30:e946343
In Press
Review article
Dangerous Intersection of Alcoholism and Othello Syndrome: A Comprehensive Review of Delusional Jealousy an...Med Sci Monit In Press; DOI: 10.12659/MSM.945616
Clinical Research
Intrathecal Morphine Enhances Postoperative Analgesia and Recovery in Robotic-Assisted Laparoscopic Partial...Med Sci Monit In Press; DOI: 10.12659/MSM.945595
Review article
Pharmacological Strategies in Dermatomyositis: Current Treatments and Future DirectionsMed Sci Monit In Press; DOI: 10.12659/MSM.944564
Clinical Research
Effect of Hyaluronic Acid on Socket Healing After Lower Impacted Third Molar Tooth Extraction in 40 Dental ...Med Sci Monit In Press; DOI: 10.12659/MSM.945386
Most Viewed Current Articles
17 Jan 2024 : Review article 6,046,164
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research 1,830,881
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 692,816
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
07 Jan 2022 : Meta-Analysis 257,285
Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Dise...DOI :10.12659/MSM.935074
Med Sci Monit 2022; 28:e935074